Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00233480 · ClinicalTrials.gov registry record · Phase 4

Statin Therapy in Heart Failure: Potential Mechanisms of Benefit

A Phase 4 study of Heart Failure, Congestive, sponsored by University of California, Los Angeles.

Completed
Registry status
Phase 4
Development phase
27
Enrollment target
1
Study location

NCT00233480 is a Phase 4 study of Heart Failure, Congestive that has completed, run by University of California, Los Angeles. The registered enrollment target is 27 participants, below the 641-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00233480, a Phase 4 study of Heart Failure, Congestive, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
Phase 4
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The goal of the investigators' study is to further understand the potentially beneficial effects of statin therapy in patients with heart failure. It is hypothesized that statins will 1) increase the heart's pumping ability 2) improve functioning of the sympathetic nervous system and 3) decrease immune activation in heart failure.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG atorvastatin

Study Locations (1)

California

  • Ahmanson-UCLA Cardiomyopathy Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2005-08
Est. Completion 2009-02
Phase Phase 4

What the Registry Record Tells You About NCT00233480

The ClinicalTrials.gov registry entry for NCT00233480 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 641-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (96% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00233480 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00233480 about?

NCT00233480 is a clinical study titled "Statin Therapy in Heart Failure: Potential Mechanisms of Benefit". The goal of the investigators' study is to further understand the potentially beneficial effects of statin therapy in patients with heart failure. It is hypothesized that statins will 1) increase the heart's pumping ability 2) improve functioning of the sympathetic nervous system and 3) decrease imm...

What is the current status of trial NCT00233480?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2005-08. Estimated completion is 2009-02.

What conditions does trial NCT00233480 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00233480?

The interventions under investigation include: placebo (DRUG), atorvastatin (DRUG).

Who is sponsoring clinical trial NCT00233480?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00233480 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.